The Filing Desk

Absci vs Capricor Therapeutics

Absci ABSI · Capricor Therapeutics CAPR · Biotechnology

Absci's revenue fell 38.2% in its latest year, and Capricor Therapeutics' fell 100.0%. Free cash flow was −$94 million at Absci and −$73 million at Capricor Therapeutics.

Side by side

AbsciCapricor Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$3M$0M
Revenue growth−38.2%−100.0%
Revenue growth a year, last 5 years−10.2%—
Gross margin——
Operating margin−4,297.0%—
Net margin−4,113.7%—
Free cash flow−$94M−$73M
Free cash flow margin−3,358.3%—
Return on capital−162.8%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count24.1%32.0%
Last close$8.45$9.53
P/E at the last close——
Insider trades, last 12 monthsbought $933,174, sold $132,328—
Piotroski F-score3 of 83 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AbsciCapricor Therapeutics
Operating margin
Percent of revenue
AbsciCapricor Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbsciCapricor Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Absci and Capricor Therapeutics pages.